A large number of 'SGLT-2 inhibitor (SGLT2i)+DPP-4 inhibitor (DPP4i)' combinations entered the market after Korea’s insurance reimbursement was extended to cover ‘SGLT-2 inhibitor + DPP-4 inhibitor’ combinations, however, their sales performance in the first year is falling short of expectations.

Of the major products that have been on the market since May, only 3 generated more than KRW 2 billion in prescriptions by the end of the year. Of the more than 30 dapagliflozin+sitagliptin combination products released since September, most prescriptions sold less than KRW 100 million by the end of the year.

In the field, prescribers are noting how the extended reimbursement is applied to th